Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response

被引:32
|
作者
Yamada, Ryoko [1 ]
Hiramatsu, Naoki [2 ]
Oze, Tsugiko [1 ]
Urabe, Ayako [1 ]
Tahata, Yuki [1 ]
Morishita, Naoki [3 ]
Kodama, Takahiro [1 ]
Hikita, Hayato [1 ]
Sakamori, Ryotaro [1 ]
Yakushijin, Takayuki [4 ]
Yamada, Akira [5 ]
Hagiwara, Hideki [10 ]
Mita, Eiji [6 ]
Oshita, Masahide [7 ]
Itoh, Toshifumi [8 ]
Fukui, Hiroyuki [11 ]
Inui, Yoshiaki [12 ]
Hijioka, Taizo [13 ]
Inada, Masami [14 ]
Katayama, Kazuhiro [9 ]
Tamura, Shinji [3 ]
Inoue, Atsuo [4 ]
Imai, Yasuharu [15 ]
Tatsumi, Tomohide [1 ]
Hamasaki, Toshimitsu [16 ]
Hayashi, Norio [10 ]
Takehara, Tetsuo [1 ]
机构
[1] Osaka Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan
[2] Osaka Rosai Hosp, Dept Gastroenterol & Hepatol, Sakai, Osaka, Japan
[3] Minoh City Hosp, Dept Gastroenterol & Hepatol, Mino, Japan
[4] Osaka Gen Med Ctr, Dept Gastroenterol & Hepatol, Osaka, Japan
[5] Sumitomo Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan
[6] Natl Hosp Org, Dept Gastroenterol & Hepatol, Osaka Natl Hosp, Osaka, Japan
[7] Osaka Police Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan
[8] Japan Community Hlth Care Org, Dept Gastroenterol & Hepatol, Osaka Hosp, Osaka, Japan
[9] Osaka Int Canc Inst, Dept Gastroenterol & Hepatol, Osaka, Japan
[10] Kansai Rosai Hosp, Dept Gastroenterol & Hepatol, Amagasaki, Hyogo, Japan
[11] Yao Municipal Hosp, Dept Gastroenterol & Hepatol, Yao, Japan
[12] Hyogo Prefectural Nishinomiya Hosp, Dept Gastroenterol & Hepatol, Nishinomiya, Hyogo, Japan
[13] Natl Hosp Org, Dept Gastroenterol & Hepatol, Osaka Minami Med Ctr, Kawachi Nagano, Japan
[14] Toyonaka City Hosp, Dept Gastroenterol & Hepatol, Toyonaka, Osaka, Japan
[15] Ikeda Municipal Hosp, Dept Gastroenterol & Hepatol, Ikeda, Osaka, Japan
[16] Natl Cerebral & Cardiovasc Ctr, Dept Gastroenterol & Hepatol, Dept Data Sci, Suita, Osaka, Japan
关键词
chronic hepatitis C; pegylated interferon; risk factor; hepatocellular carcinoma; direct-acting antivirals; EARLY TUMOR RECURRENCE; INTERFERON THERAPY; PLUS RIBAVIRIN; ALPHA; IMPACT;
D O I
10.1111/hepr.13310
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim In patients with chronic hepatitis C, hepatocellular carcinoma (HCC) occurs at a certain frequency, even if a sustained virologic response (SVR) is achieved by antiviral treatment. Old age, liver fibrosis, and high post-treatment alpha-fetoprotein (AFP) level are typical risk factors of post-SVR HCC. We examined whether the frequencies and factors of HCC in patients with an SVR achieved from interferon treatment changed. Methods Among patients prospectively registered for pegylated interferon and ribavirin treatment, 2021 with an SVR without HCC development during the treatment period were followed up. The mean observation period was 49.5 +/- 26.2 months. Results The multivariable Cox regression analysis showed that older age, diabetes mellitus, advanced liver disease, and higher post-treatment AFP level were the independent risk factors throughout the observation period. The annual occurrence rate of HCC was 0.74% in the third year, 0.54% in the fourth year, and 0.40% in the fifth year; it gradually decreased from the third year. Because the time course hazards for HCC changed at 48 months, we separately analyzed its risk factors before and after this change point. The multivariable Cox regression analysis showed that the four above-mentioned factors were significantly related to HCC development within 4 years. Conversely, the univariable Cox regression analysis only identified diabetes mellitus as a significant factor for HCC development after 4 years. Conclusion The frequency of HCC in hepatitis C patients who achieved an SVR from interferon treatment decreased during the observation period, and its risk factors changed between the early and late periods.
引用
收藏
页码:570 / 578
页数:9
相关论文
共 50 条
  • [21] Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy
    Chang, Kuo-Chin
    Ye, Yi-Hao
    Wu, Cheng-Kun
    Lin, Ming-Tsung
    Tsai, Ming-Chao
    Tseng, Po-Lin
    Hu, Tsung-Hui
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2018, 117 (11) : 1011 - 1018
  • [22] Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis
    Cheinquer, Nelson
    Cheinquer, Hugo
    Wolff, Fernando H.
    Coelho-Borges, Silvia
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2010, 14 (05): : 457 - 461
  • [23] The sustained virologic response of nonresponder hepatitis C virus patients with retreatment
    Akhan, Sila Cetin
    Gurel, Erdem
    Sayan, Murat
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2011, 54 (01) : 81 - 84
  • [24] VFMAP predicted hepatocellular carcinoma development in patients with chronic hepatitis C who were treated with direct-acting antiviral and achieved sustained virologic response
    Matono, Tomomitsu
    Tada, Toshifumi
    Nishimura, Takashi
    Takashima, Tomoyuki
    Aizawa, Nobuhiro
    Ikeda, Naoto
    Shiomi, Hideyuki
    Enomoto, Hirayuki
    Iijima, Hiroko
    JOURNAL OF MEDICAL ULTRASONICS, 2024, 51 (02) : 293 - 300
  • [25] Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy
    Sewell, Justin L.
    Stick, Kristine M.
    Monto, Alexander
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2009, 21 (02) : 225 - 229
  • [26] Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study
    Nagaoki, Yuko
    Aikata, Hiroshi
    Nakano, Norihito
    Shinohara, Fumi
    Nakamura, Yuki
    Hatooka, Masahiro
    Morio, Kei
    Kan, Hiromi
    Fujino, Hatsue
    Kobayashi, Tomoki
    Fukuhara, Takayuki
    Masaki, Keiichi
    Ono, Atsushi
    Nakahara, Takashi
    Kawaoka, Tomokazu
    Miki, Daiki
    Tsuge, Masataka
    Hiramatsu, Akira
    Imamura, Michio
    Takahashi, Shoichi
    Kawakami, Yoshiiku
    Ochi, Hidenori
    Chayama, Kazuaki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (05) : 1009 - 1015
  • [27] Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct-acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance
    Tada, Toshifumi
    Kumada, Takashi
    Matono, Tomomitsu
    Nakamura, Shinichiro
    Sue, Masahiko
    Matsuo, Yu
    Takatani, Masahiro
    Iijima, Hiroko
    Tanaka, Junko
    JGH OPEN, 2022, 6 (07): : 462 - 469
  • [28] Differences in molecular alterations of hepatocellular carcinoma between patients with a sustained virological response and those with hepatitis C virus infection
    Hayashi, Takehiro
    Tamori, Akihiro
    Nishikawa, Manabu
    Morikawa, Hiroyasu
    Enomoto, Masaru
    Sakaguchi, Hiroki
    Habu, Daiki
    Kawada, Norifumi
    Kubo, Shoji
    Nishiguchi, Shuhei
    Shiomi, Susumu
    LIVER INTERNATIONAL, 2009, 29 (01) : 126 - 132
  • [29] Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection
    Ida, Hiroshi
    Hagiwara, Satoru
    Kono, Masashi
    Minami, Tomohiro
    Chishina, Hirokazu
    Arizumi, Tadaaki
    Takita, Masahiro
    Yada, Norihisa
    Minami, Yasunori
    Ueshima, Kazuomi
    Nishida, Naoshi
    Kudo, Masatoshi
    DIGESTIVE DISEASES, 2017, 35 (06) : 565 - 573
  • [30] Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response
    Park, Jung Eun
    Nguyen, Vy H.
    Tsai, Pei-Chien
    Toyoda, Hidenori
    Leong, Jennifer
    Guy, Jennifer E.
    Yeh, Ming-Lun
    Huang, Chung-Feng
    Yasuda, Satoshi
    Abe, Hiroshi
    Hsu, Yao-Chun
    Tseng, Cheng-Hao
    Liu, Joanne
    Chen, Yao-Li
    Lin, Ping-Yi
    Jun, Dae Won
    Yoshimaru, Yoko
    Ogawa, Eiichi
    Ishigami, Masatoshi
    Enomoto, Masaru
    Tamori, Akihiro
    Uojima, Haruki
    Wang, Xiao Zhong
    Xu, Qiang
    Takahashi, Hirokazu
    Eguchi, Yuichiro
    Inoue, Kaori
    Huang, Daniel Q.
    Zhao, Wen Jing
    Chuang, Wan-Long
    Dai, Chia-Yen
    Huang, Jee-Fu
    Barnett, Scott
    Maeda, Mayumi
    Cheung, Ramsey
    Landis, Charles
    Tanaka, Yasuhito
    Roberts, Lewis R.
    Schwartz, Myron E.
    Kumada, Takashi
    Yu, Ming-Lung
    Nguyen, Mindie H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (06) : 742 - 751